Basilea’s partner Asahi Kasei Therapeutics starts a pediatric clinical trial in Japan for the antifungal Cresemba, widening the drug’s potential patient base
Executive summary: Basilea disclosed that Asahi Kasei Therapeutics has begun a clinical study in Japan testing Cresemba (isavuconazole) in pediatric patients. Expanding Cresemba’s use to children could meet a significant unmet need for antifungal therapies in pediatrics and open a new revenue stream for the partners.
Who is involved: Basilea (Switzerland), Asahi Kasei Therapeutics (Japan), pediatric patients in Japan, and implicitly the Japanese regulatory authority (PMDA).
Likely next: The study will continue with patient enrollment and data collection, leading to interim safety readouts and potential regulatory submissions for a pediatric indication.
Basilea’s announcement that its Japanese partner Asahi Kasei Therapeutics has launched a pediatric clinical trial for Cresemba (isavuconazole) marks a concrete step toward expanding the antifungal’s label beyond adults. The study, being conducted in Japan, will collect safety and efficacy data in children, a population for which few antifungal agents have approved indications. If the trial yields favorable results, it could support a supplemental filing that would allow Cresemba to be used in pediatric invasive fungal infections, a therapeutic area where clinicians often rely on off‑label use of older agents with broader side‑effect profiles. From a business perspective, widening Cresemba’s indications could open an additional revenue stream for Basilea, particularly in markets where pediatric fungal infections represent a niche but growing unmet need. The partnership with Asahi Kasei Therapeutics also reinforces Basilea’s reliance on local collaborators to navigate region‑specific regulatory pathways, potentially accelerating approval in Japan and serving as a model for similar efforts in other Asia‑Pacific countries. Near‑term, the trial’s progress will be watched for any data releases that might trigger regulatory discussions, though the timeline for a possible label extension remains contingent on the study’s outcome.
What's next — scenarios
Base: Study proceeds as planned (60%)
The trial enrolls pediatric patients and generates safety/efficacy data within the expected timeline, supporting a future pediatric indication for Cresemba.
- Patient enrollment continues without major delays
- No safety signals emerge in early monitoring
- Interim data readout anticipated in 12‑18 months
Upside: Positive efficacy accelerates approval (25%)
Strong efficacy results enable an accelerated regulatory review, potentially bringing a pediatric Cresemba label to market earlier than expected.
- Interim analysis shows statistically significant efficacy vs. comparator
- Regulatory agency grants fast‑track or priority review
- Manufacturing scale‑up for pediatric formulation begins
Downside: Safety concerns or delays (15%)
Adverse events or enrollment challenges slow the study, postponing any pediatric label expansion and increasing development costs.
- Serious adverse events trigger a clinical hold
- Enrollment falls short of targets, extending timeline
- Requests for additional safety data from regulators
What to watch
- Interim safety data readout expected within 12‑18 months of study start
- Target completion of patient enrollment (if disclosed by the sponsors)
- Any regulatory meeting or feedback from Japan’s PMDA regarding the pediatric study
- Publication of preliminary results in a medical journal or conference
Timeline
- — Basilea announces start of clinical study by partner Asahi Kasei Therapeutics in Japan with antifungal Cresemba® (isavuconazole) in pediatric patients (GlobeNewswire)
Analysis — what this means
Sectors affected
- Pediatric antifungal therapeutics
- Antifungal drug development